Abstract: THE MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL DOI: 10.14744/SEMB.2021.35902 Med Bull Sisli Etfal Hosp 2022;56(2):189–195 Original Research Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit Sultan Acar Sevinc,1 Ayse Surhan Cinar,1 Nermin Balta Basi,1 Serkan Islamoglu,1 Mustafa Altinay,1 Haci Mustafa Ozdemir2 Seyhan Metin,1 Tugba Yucel,1 Department of Anesthesiology and Reanimation, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey 2 Department of Orthopedics, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey 1 Abstract Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients’ data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9–24) days with favipiravir and 8.5 (5–12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5–15) days and 4 (3–9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001). Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed. Keywords: COVID-19, intensive care unit, favipiravir, lopinavir-ritonavir, mortality Please cite this article as ”Acar Sevinc S, Surhan Cinar A, Balta Basi N, Metin S, Yucel T, Islamoglu S, et al. Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit. Med Bull Sisli Etfal Hosp 2022;56(2):189–195”. C OVID-19 is the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and may present in different clinical scenarios: About 80% of patients present with mild, 13.8% present with severe disease, and 6.1% with critical disease.[1] According to the guidelines published by the Ministry of Health in Turkey, patients with severe and critical disease were advised to be admitted to intensive care unit (ICU).[2] Turkey diagnosed Address for correspondence: Sultan Acar Sevinc, MD. Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi, Anesteziyoloji ve Reanimasyon Bolumu, Istanbul, Turkey Phone: +90 212 373 50 00 E-mail: sultanacar34@hotmail.com Submitted Date: July 13, 2021 Accepted Date: September 18, 2021 Available Online Date: June 28, 2022 © Copyright 2022 by The Medical Bulletin of Sisli Etfal Hospital - Available online at www.sislietfaltip.org OPEN ACCESS This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/). 190 its first COVID-19 case on March 11, 2020. A detailed treatment algorithm was published on April 14,..